The Clinical Core of the UAB CFAR was established in 1988 to provide a bridge between patients attending the AIDS Outpatient Clinics (1917 Clinic and the Family Clinic) and the basic scientists working in the laboratories of the Center. The Center provides support to investigators through a clinical database, a clinical specimen repository, clinical trials, and ongoing programs in clinical pharmacology. The clinical database maintains quality assured clinical data on all outpatients seen in both the adult and children's HIV Outpatient Clinics. Baseline demographics along with critical clinical information is stored in a centralized computer. Blood specimens are collected on a periodic basis and stored in a central specimen repository. This repository has a computerized record of every specimen collected over the five years of clinical core's existence, yielding easy retrievability of specimens desired for a specific basic science or clinical science study. The specific objectives of the Core are to: (1) establish and maintain effective communication between clinical and basic scientists in order to develop multidisciplinary collaborative projects which study the nature and pathogenesis of HIV disease; (2) provide clinical specimens from well-characterized patients to basic science investigators through the establishment of a clinical specimen repository which is linked to a computerized database; (3) conduct state-of-the-art clinical trials on novel therapeutic agents and regimens for HIV-related disorders; (4)link the clinical trials effort with development of novel markers of anti-retroviral activity, new approaches in investigative pharmacology, and the discovery of new agents through an ongoing drug discovery program and experimental therapeutics program. The Clinical Core has been extremely successful, providing service to 46 CFAR investigators on over 100 specific projects. The Center has conducted 46 clinical trials, focusing on primary infection (369 patients enrolled), opportunistic infections (222 patients enrolled), and nutritional/cytokine studies (66 patients enrolled). These studies have encompassed the full range of trial designs from Phase I early pharmacokinetic studies to Phase III multicentered clinical efficacy trials. Future directions include the establishment of a Vaccine Evaluation Unit, an Outpatient Dental Facility for the Study of HIV-related oral disease, to modify the clinical database to provide a foundation for studies in behavioral science, and to develop a Women's Clinic for studies of HIV- related disease occurring in this population.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI027767-09
Application #
6234923
Study Section
Project Start
1997-03-01
Project End
1998-02-28
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
9
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Nag, Mukta; De Paris, Kristina; E Fogle, Jonathan (2018) Epigenetic Modulation of CD8? T Cell Function in Lentivirus Infections: A Review. Viruses 10:
Barr, Fiona D; Ochsenbauer, Christina; Wira, Charles R et al. (2018) Neutrophil extracellular traps prevent HIV infection in the female genital tract. Mucosal Immunol 11:1420-1428
Holdbrooks, Andrew T; Britain, Colleen M; Bellis, Susan L (2018) ST6Gal-I sialyltransferase promotes tumor necrosis factor (TNF)-mediated cancer cell survival via sialylation of the TNF receptor 1 (TNFR1) death receptor. J Biol Chem 293:1610-1622
Williams, Adele P; Waters, Alicia M; Stewart, Jerry E et al. (2018) A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro. J Surg Res 228:54-62
Dixit, Saurabh; Sahu, Rajnish; Verma, Richa et al. (2018) Caveolin-mediated endocytosis of the Chlamydia M278 outer membrane peptide encapsulated in poly(lactic acid)-Poly(ethylene glycol) nanoparticles by mouse primary dendritic cells enhances specific immune effectors mediated by MHC class II and CD4+ T cells. Biomaterials 159:130-145
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Ladowski, Joseph M; Martens, Gregory R; Reyes, Luz M et al. (2018) Examining the Biosynthesis and Xenoantigenicity of Class II Swine Leukocyte Antigen Proteins. J Immunol 200:2957-2964
Peng, Binghao J; Carlson, Jonathan M; Liu, Michael K P et al. (2018) Antisense-Derived HIV-1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection. J Virol 92:
Shi, Bi; Geng, Jianlin; Wang, Yin-Hu et al. (2018) Foxp1 Negatively Regulates T Follicular Helper Cell Differentiation and Germinal Center Responses by Controlling Cell Migration and CTLA-4. J Immunol 200:586-594

Showing the most recent 10 out of 955 publications